Vectura Group PLC (VEC.L)

About

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.66
Market Cap(Mil.):	£532.24
Shares Outstanding(Mil.):	665.30
Dividend:	--
Yield (%):	--

Financials

	VEC.L	Industry	Sector
P/E (TTM):	--	28.54	30.58
EPS (TTM):	-0.13	--	--
ROI:	-12.26	13.15	12.84
ROE:	-13.90	15.15	15.02

Latest News about VEC.L

BRIEF-Sosei Says Does Not Intend To Make An Offer For Vectura

* CONFIRMS THAT IT DOES NOT INTEND TO MAKE AN OFFER FOR VECTURA

24 Apr 2018

BRIEF-Vectura Says CFO Decided To Leave Group

* CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR ANDREW DERODRA HAS DECIDED TO LEAVE GROUP

20 Apr 2018

Vectura posts wider 2017 loss, revenue rise

British drugmaker Vectura reported a worse-than-expected pretax loss for the full year on Wednesday, dragged by lower royalties and higher costs related to the SkyePharma deal.

21 Mar 2018

CORRECTED-UPDATE 1-UK's Vectura posts wider 2017 loss, revenue rise

March 21 British drugmaker Vectura reported a worse-than-expected pretax loss for the full year on Wednesday, dragged by lower royalties and higher costs related to the SkyePharma deal.

21 Mar 2018